Laser/drug treatment for AMD (advanced micro devices) lasts two years:
This article was originally published in Clinica
Executive Summary
Initial results from a Phase III trial of Visudyne phototherapy for treating age-related macular degeneration (AMD) have shown that its benefits are sustained over a two-year period. The treatment, in which the drug is injected into the arm and non-thermal laser light is shined on the eye, is under development by CIBA Vision and Vancouver, Canada-based QLT PhotoTherapeutics. It is in a Phase III trial for wet AMD and a Phase IIIb trial for choroidal neovascularisation.
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.